LEIDEN, NETHERLANDS--(Marketwire - March 25, 2009) -
Leiden, The Netherlands, March 25, 2009. Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) (PINKSHEETS: PHGUF) announced today that the Company’s Annual General Meeting of Shareholders (AGM) will be held at the Pharming headquarters in Leiden, the Netherlands on 15 April 2009 commencing at 15.00 pm CET.
All documentation relating to the AGM will be available on Pharming’s website as of 31 March 2009, including an electronic version of the Annual Report for the year 2008. Copies of this report will be available as of 1 April 2009. If you wish to receive a copy, please fill out the request from on Pharming’s website: www.pharming.com.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human Lactoferrin for use in food products and one product in early stage clinical development - Prodarsan® for Cockayne Syndrome. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
Contact:
Sijmen de Vries, Pharming Group NV, T: +31 (0)71 52 47 400
Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
ATTACHMENTS: http://hugin.info/132866/R/1300479/296948.pdf
Copyright © Hugin AS 2009. All rights reserved.
